Alcon, Aurion Reach Accord in Dispute Over Public Offering

Fast-tracked cross-appeals in Delaware by Alcon Research LLC and Aurion Biotech Inc. have been closed, now that Alcon has bought a majority stake in the company that’s developing a potentially groundbreaking drug to treat corneal disease.

The parties notified the Delaware Supreme Court in a March 6 letter that they were involved in settlement negotiations. Alcon, the world’s largest eye care company, announced March 26 it was buying a majority stake in Aurion to advance its cell therapy for corneal endothelial disease into Phase 3 trials during the second half of 2025. Delaware’s top court granted the voluntary dismissal of ...